Elsevier

Cytotherapy

Volume 6, Issue 2, April 2004, Pages 88-98
Cytotherapy

DCs as targets for vaccine design

https://doi.org/10.1080/14653240410005276Get rights and content

The increasingly stringent requirements laid down by regulatory authorities have brought to an end the largely empirical design of vaccines. Vaccines must now be designed rationally, in order that appropriate immune responses are elicited with few or no side effects. The DC plays a pivotal role in determining the type of immune response that ensues following exposure of the host to an Ag. In this review, we identify some of the features and properties of DCs, and how these properties can be exploited in the design of smart vaccines.

Introduction

DCs are the most potent APCs used by the immune system, and are therefore a very attractive target for the designer Ags that can be used either as conventional vaccines or for DC-based therapies. As a result of the technical advances made in the last decade in isolating, purifying, and propagating DCs, we are now able to study their functions. Genechip technologies and sophisticated flow cytometric techniques have allowed multiple subsets of DCs to be identified by their specific surface markers, and have also opened the way for discovery of the molecular mechanisms that determine their functions. Different DC subsets and DCs at different stages of development or activation express distinct surface molecules and secrete cytokines that selectively determine the type of immune response which is induced. These properties suggest that DC subsets are amenable to specific targeting through these surface molecules and, consequently, allow greater efficacy for vaccine delivery. As the role of different DC subsets becomes known, it is likely that even more efficient vaccines will be developed to elicit particular types of immune response.

Section snippets

DC maturation and activation

The primary function of DCs is to capture Ag, process it and present antigenic peptides to activate specific T cells [1]. Found in most lymphoid and non-lymphoid organs of the body, DCs are widely distributed, acting as sentinels for tumor and infection detection [2]. DCs have long been considered to be the main APCs involved in priming both CD4 and CD8 T lymphocytes. DCs are perfectly equipped for their role as initiators of the immune response [3,4]. They express both Class I and Class II MHC

MHC Class I and II Ag presentation—the ‘Classical’ pathways

Typically, MHC Class I molecules present endogenous self-Ags or pathogen-derived Ags that are synthesized within a cell. Exogenous (extracellular) Ags are usually processed through the MHC Class II pathway, and are then presented to CD4+ T cells. Cytotoxic (CD8+) T cells (CTL) recognize peptides that are presented by MHC Class I molecules, while helper (CD4+) T cells recognize Ags presented on MHC Class II molecules. All nucleated cells possess MHC Class I molecules, but MHC Class II molecule

DC subtypes

DCs in mice and humans are a heterogeneous population of cells that can be segregated into several phenotypically defined populations. Much effort is currently directed at elucidating the functional relevance of each of these populations.

Human DC subtypes in vivo

The study of human DCs has been hampered by the lack of availability of human lymphoid tissues that allow direct comparison with murine DC subsets. In contrast to the many DC subtypes identified in the mouse, relatively few DC subsets of mature human DCs have been identified (Table 4).

In general, human DC populations express the markers CD11c, CD11b and CD4, but the human equivalent of the murine CD8α+ DC remains elusive. Langerhans cells, a subset of human DCs, are characterized by the

Host—pathogen interactions and in vivo identification of DC subsets for priming

By monitoring the environment, and detecting and reacting to Ags, DCs form a link between the innate and adaptive immune systems. A newly emerging theme in DC biology is that of understanding the specialized functional role that DC subsets play in triggering different components of the immune system.

The DCs responsible for CTL priming following Herpes simplex 1 (HSV-1) infection appears to be the CD8+(CDllb_) DC [45]. This is the same subset of DC that preferentially cross-present soluble and

Determining the outcome of Ag delivery and presentation using DC subsets

The last decade has seen the execution of a large number of technically precise experiments, particularly in murine models, that have uncovered a large array of DC subsets in vivo. Functional definition of the importance of these specialized DC subsets in an immune response has been much slower and is only now beginning to emerge. These advances have opened the door to specific customized targeting of Ags to DC populations, in attempts to generate effective Ag delivery systems that will improve

Targeting DCs to induce tolerance

In most situations, the objective of vaccination is to initiate or enhance an immune response, however, controlling an immune response (inducing anergy or tolerance) is equally complex. When a DC captures Ags from a pathogen, for example a virus, then both viral and self-Ags will be presented to the immune system in order to activate the cellular arm of the immune system to eliminate the virus. Thus, a mechanism is required to allow removal or control of the virus without attacking the body's

Developing smart vaccines

The variety of DC phenotypes, and the multiplicity of different lymphoid cells with which DCs can engage, indicate that once they have encountered Ag, DCs are intimately involved in determining the nature of the ensuing immune response. It is not surprising, therefore, that their importance in re-thinking vaccine design has already been described by others (for review see Reference 60).

DCs have been described as’ Nature's adjuvants’ and, indeed, once they can be persuaded to take an interest in

Obstacles facing the study of DCs

Although the idea of using DCs as vehicles for vaccine delivery and for cell-based therapy is not new (for review see Reference 60), their utility has been hampered by a number of obstacles:

  • Although DCs are widely dispersed through the host, they are present only in small numbers

  • Difficulties have been encountered in developing robust isolation procedures for DCs

  • In vitro culture conditions cause phenotypic changes in DCs that are not representative of the corresponding in vivo isolates; related

Acknowledgements

We would like to acknowledge Meredith O’Keeffe for her critical reading of this manuscript. Gabrielle Belz is a Wellcome Trust Senior Overseas Research Fellow. David Jackson is a Principal Research Fellow with the National Health and Medical Research Council of Australia, and Program Leader of the Cooperative Research Centre for Vaccine Technology.

References (68)

  • D.N. Hart

    Dendritic cells: unique leukocyte populations which control the primary immune response

    Blood

    (1997)
  • Y. Osugi et al.

    Myeloid blood CDllc(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes

    Blood

    (2002)
  • K.P. MacDonald et al.

    Characterization of human blood dendritic cell subsets

    Blood

    (2002)
  • Y.J. Liu

    Dendritic cell subsets lineages and their functions in innate and adaptive immunity

    Cell

    (2001)
  • S. Hugues et al.

    Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells

    Immunity

    (2002)
  • C.J. Fitzmaurice et al.

    The assembly and immunological properties of non-linear synthetic immunogens containing T-cell and B-cell determinants

    Vaccine

    (1996)
  • L. BenMohamed et al.

    Lipopeptide vaccines-yesterday, today, and tomorrow

    Lancet Infect Dis

    (2002)
  • W. Zeng et al.

    Totally synthetic lipid- containing polyoxime peptide constructs are potent immunogens

    Vaccine

    (2000)
  • K. Shortman et al.

    Dendritic cell development: multiple pathways to nature's adjuvants

    Stem Cells

    (1997)
  • N. Jonas et al.

    Manipulation of dendritic cells for immunotherapy of tumours

    Today Life Sci

    (2000)
  • J. Banchereau et al.

    Dendritic cells and the control of immunity

    Nature

    (1998)
  • J. Banchereau et al.

    Immunobiology of dendritic cells

    Annu Rev Immunol

    (2000)
  • R. Steinman

    The dendritic cell system and its role in immunogenicity

    Annu Rev Immunol

    (1991)
  • N.A. Fanger et al.

    (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells

    J Immunol

    (1996)
  • M.E. Esposito-Farese et al.

    Membrane and soluble Fc gamma RII/III modulate the antigen-presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigens

    J Immunol

    (1995)
  • C. Reis e Sousa et al.

    Phagocytosis of antigens by Langerhans cells in vitro

    JExp Med

    (1993)
  • F. Castellino et al.

    etal. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex Class I antigen presentation via two distinct processing pathways

    J Exp Med

    (2000)
  • D. Arnold-Schild et al.

    Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells

    J Immunol

    (1999)
  • N. Platt et al.

    Class A scavenger receptors and the phagocytosis of apoptotic cells

    Biochem Soc Trans

    (1998)
  • F. Sallusto et al.

    Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex Class II compartment: downregulation by cytokines and bacterial products

    J Exp Med

    (1995)
  • W. Jiang et al.

    The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing

    Nature

    (1995)
  • P. Guermonprez et al.

    Antigen presentation and T cell stimulation by dendritic cells

    Annu Rev Immunol

    (2002)
  • F. Geissmann et al.

    A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes

    J Immunol

    (2001)
  • J.M. den Haan et al.

    Constitutive versus activation- dependent cross-presentation of immune complexes by CD8+ and CD8_ dendritic cells in vivo

    J Exp Med

    (2002)
  • Cited by (9)

    • A tetracycline expression system in combination with Sox9 forcartilage tissue engineering

      2014, Biomaterials
      Citation Excerpt :

      The injury or degeneration of cartilage which harms human health is related to and caused by many diseases, such as trauma-induced injuries, age-related degenerative joint diseases, osteoarthritis, and rheumatoid arthritis [1].

    • An APC for every occasion: Induction and expansion of human Ag-specific CD4 and CD8 T cells using cellular and non-cellular APC

      2004, Cytotherapy
      Citation Excerpt :

      Requirements for ex vivo use are less stringent. Numerous clinical trials using DC vaccines are now published or underway, and a variety of techniques forgenerating clinical grade DC have been described [85–87]. For ex vivo selection and expansion of T cells for clinical use, numerous techniques abound for the use of PHA blasts [51], EBV-LCL [88–90], monocytes [44], DC [16,91–94] and artificial APC [73].

    View all citing articles on Scopus
    View full text